Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Roche Adds To Its Immuno-Oncology Investments With Inovio Licensing Deal

This article was originally published in The Pink Sheet Daily

Executive Summary

Swiss pharma licenses rights to a pair of preclinical, multi-antigen DNA immunotherapies for prostate cancer and hepatitis B, as well as delivery technology. Inovio gets $10 million up front and can earn milestones up to $412.5 million.

You may also be interested in...



Senators, State AGs Differ On Whether Further Federal Regulation Needed For OTC Hearing Aids

Sens. Warren and Grassley say federal regulation is needed to ensure consumers in all states benefit from OTC hearing aids. State AGs, on the other hand, have asked the FDA to “define preemption terms in a way that recognizes the important role state and local entities play in protecting consumers.”

Beautycounter Will Have New CEO In February; Executive Appointments In Brief

Former Shiseido and L’Oreal executive Marc Rey will lead clean beauty company Beautycounter, effective on 1 February, succeeding founder Gregg Renfrew, now executive chair and chief brand officer. More executive appointment news from International Flavors & Fragrances and Kao Corp.

Minute Insight: Confidence Plus Shows Medical Device Innovation Can Start In The Home

Ostomy bags can leak and cause problems for patients and health care workers, so Anne Inch created a device in her attic to solve that problem and has begun to commercialize it.

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

PS076223

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel